David Hassman is a Primary Care physician affiliated with Hassman Research Institute. OpenAlex indexes 25 publications with 1,238 citations (h-index 13); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Sponsor: Elcelyx Therapeutics, Inc.
- T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza
Sponsor: MDVI, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202518 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Novo Nordisk IncProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Similar KOLs
Other experts from the same institution or the same specialty.
Fei Wang, MD
Cornell University
Michael Hassman, DO
Barbara Rizzardi, MD
Kimball Johnson, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”